# US 2013/0251669 A1 · Treatment of diabetes using g-csf and hyperbaric oxygen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251669 A1
- Document ID: US20130251669A1
- Status: Published application
- Kind: A1
- Application number: 13/896,836
- Filed: 2013-05-17
- Published: 2013-09-26
- Earliest claimed: 2010-10-19
- Assignees: Advanced Neuroregenerative Therapies, LLC.
- Applicants: Advanced Neuroregenerative Therapies, LLC
- Inventors: Dipnarine MAHARAJ
- Web page: https://patentgrep.com/patent/US20130251669A1

## CPC

- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/08: Vasodilators for multiple indications
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating endothelial cells comprising: inducing vasodilation in a patient; and administering a composition including a stem cell proliferation agent to the patient.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method for causing glucose levels to trend lower in a patient having diabetes, both during and after treatment with a combination of vasodilation and stem cell proliferation comprising:
exposing said patient to an agent and/or a therapy to induce vasodilation;
exposing said patient to a stem cell proliferation agent; and
further exposing said patient to an agent/or therapy to induce vasodilation;
wherein said patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended.

### Claim 22 (depends on 21)

The method of claim 21, where the step of exposing said patient to an agent and/or a therapy to induce vasodilation includes administering hyperbaric oxygen treatment for a period of about five consecutive days.

### Claim 23 (depends on 21)

The method of claim 21 wherein the step of exposing said patient to a stem cell proliferation agent includes administering a granulocyte colony stimulating factor, a derivative or isomer thereof for a period of about seven consecutive days, in an amount effective to result in stem cell mobilization;
whereby said mobilized stem cells passively migrate into the patient's bloodstream.

### Claim 24 (depends on 23)

The method of claim 23 wherein said mobilized stem cells are pluripotent stem cells.

### Claim 25 (depends on 21)

The method of claim 21 wherein the step of further exposing said patient to an agent and/or a therapy to induce vasodilation includes administering hyperbaric oxygen treatment for a period of about five consecutive days.

### Claim 26 (depends on 21)

The method of claim 21 wherein the agent or therapy to induce vasodilation includes a pharmaceutical agent which promotes vasodilation, hyperbaric oxygen therapy and a combination thereof.

### Claim 27 (depends on 21)

The method of claim 21 wherein the stem cell proliferation agent is a granulocyte colony stimulating factor, a derivative or isomer thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the stem cell proliferation agent is administered at a dose of about 300 μg to about 960 μg per day.

### Claim 29 (depends on 21)

The method of claim 21 further comprising a step of extracting stem cells subsequent to treatment with a stem cell proliferation agent and reinfusing said stem cells into said patient.

### Claim 30

A method for causing glucose levels to trend lower in a patient having diabetes, both during and after stem cell proliferation treatment comprising:
inducing stem cell proliferation by administering a granulocyte colony stimulating factor, a derivative or isomer thereof for a period of about seven consecutive days, in an amount effective to result in stem cell mobilization;
providing a waiting period of about eight to fourteen days during which no active treatment is conducted;
further inducing stem cell proliferation by administering a granulocyte colony stimulating factor, a derivative or isomer thereof for a period of about seven consecutive days, in an amount effective to result in stem cell mobilization;
further providing a waiting period of about eight to fourteen days during which no active treatment is conducted; and
further inducing stem cell proliferation by administering a granulocyte colony stimulating factor, a derivative or isomer thereof for a period of about seven consecutive days, in an amount effective to result in stem cell mobilization;
wherein said patient's blood glucose level begins trending lower subsequent to initiation of treatment and continues to trend lower after active treatment has ended.

### Claim 31 (depends on 30)

The method of claim 30, wherein the stem cell proliferation agent is administered at a dose of about 300 μg to about 960 μg per day.

### Claim 32 (depends on 30)

The method of claim 30 further comprising a step of extracting stem cells subsequent to treatment with a stem cell proliferation agent and reinfusing said stem cells into said patient.
